Appetite Suppressants as Adjuncts in the Treatment of Obesity
- The Prevalence of Cardiac Valvular Insufficiency Assessed by Transthoracic Echocardiography in Obese Patients Treated with Appetite-Suppressant Drugs. Khan, Mehmood A.; Herzog, Charles A.; St. Peter, John V.; Hartley, Guilford G.; Madlon-Kay, Richard; Dick, Candace D.; Asinger, Richard W.; Vessey, John T. // New England Journal of Medicine;09/10/98, Vol. 339 Issue 11, p713
Background: After case reports of cardiac-valve abnormalities related to the use of appetite suppressants were published, we undertook a study to determine the prevalence of the problem using transthoracic echocardiography. Methods: We examined patients who had taken dexfenfluramine alone,...
- Orlistat for obesity? // Consumer Reports on Health;Jul99, Vol. 11 Issue 7, p7
Provides information on orlistat, an obesity drug that suppresses appetite. Clinical trial results; Mechanism of action; Side effects; Need for diet and exercise to ensure that weight loss will last.
- The weight is over. // Men's Health;Jun98, Vol. 13 Issue 5, p38
Presents information on Meridia, an anti-obesity drug approved by the United States Food and Drug Administration. How Meridia reduces the hunger of a person; Advantage of Meridia from other anti-obesity drug.
- Diet pills. Raeburn, Paul // Glamour;Aug96, Vol. 94 Issue 8, p42
Focuses on questions about the value of diet drugs. Food and Drug Administration's (FDA) approval of Redux or dexfenfluarmine; Risk of primary pulmonary hypertension; Importance of regular exercise; Redux's suppression of hunger pangs by acting on serotonin; Maintaining weight loss; Research...
- Diet pills are coming back. Toufexis, Anastasia; Park, Alice // Time International (South Pacific Edition);5/20/96, Issue 21, p63
Reports on the approval of the first antiobesity drug, called dexfenfluramine, in 23 years by health officials in the United States. Brand name, drug will be sold under; Historic information on the diet pill; Effectiveness of the drug; Expectations to approve more diet drugs; Safety of the...
- Drugs for obesity are last resort treatment. Bower, Hilary // BMJ: British Medical Journal (International Edition);06/07/97, Vol. 314 Issue 7095, p1643
States that appetite suppressant drugs should be prescribed as a last resort treatment for obese patients in Great Britain. Crackdown on inappropriate use of slimming drugs by the Royal College of Physicians of London; Benefits obese patients may get from desfenfluramine; Side effects of taking...
- Efficacy and Tolerability of Orlistat in Obese Patients. Nuovo, Jim // American Family Physician;8/1/2000, Vol. 62 Issue 3, p649
Presents an abstract of the study `Orlistat in the long-term treatment of obesity in primary care settings,' by J. Hauptman, et al., from the February 2000 issue of `Archives of Family Medicine.'
- Double-blind Evaluation of Mazindol in Refractory Obesity. Smith, R.G.; Innes, J.A.; Munro, J.F. // British Medical Journal;8/2/1975, Vol. 3 Issue 5978, p284
Evaluates the effect of mazindol on refractory obesity. Stimulation of the central nervous system; Decrease in body mass index; Role of anorectic agents in the modification of eating habits.
- Phen/fen combination for weight control. R.M.D. // Cortlandt Forum;7/25/96, Vol. 9 Issue 7, p137
Provides information on the safety and proper administration of phentermine and fenfluramine used in combination for appetite suppression. Effectiveness in treating obesity; How the agents act as appetite depressants; Recommended use of the agents as part of a comprehensive weight control...